Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-68.65M | $-1.06 |
| 2024 | $0.00 | $-52.40M | $-0.60 |
| 2023 | $0.00 | $-60.36M | $-2.09 |
| 2022 | $0.00 | $-25.74M | $-1.88 |
| 2021 | $0.00 | $8.42M | $0.40 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.22 per share
Typical surprise -10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.21 vs $-0.19miss
- Thu, May 7$-0.22 vs $-0.17miss
- Thu, Mar 19$-0.49 vs $-0.18miss
- Thu, Nov 13$-0.21 vs $-0.19miss
- Thu, Aug 14$-0.17 vs $-0.19beat
- Thu, May 8$-0.19 vs $-0.17miss
Estimates and results for ZURA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ZURAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsbusinesswire.com·4d ago·Positive
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “The second quarter was
View source ↗